Mayinglong Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 27.96%

Mayinglong Pharmaceutical Group Co Ltd (600993) has an Asset Resilience Ratio of 27.96% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥1.58 Billion
≈ $230.71 Million USD Cash + Short-term Investments

Total Assets

CN¥5.64 Billion
≈ $825.21 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Mayinglong Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check Mayinglong Pharmaceutical Group Co Ltd (600993) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600993 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.58 Billion 27.96%
Total Liquid Assets CN¥1.58 Billion 27.96%

Asset Resilience Insights

  • Very High Liquidity: Mayinglong Pharmaceutical Group Co Ltd maintains exceptional liquid asset reserves at 27.96% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Mayinglong Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Mayinglong Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Mayinglong Pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 9.31% CN¥506.09 Million
≈ $74.06 Million
CN¥5.44 Billion
≈ $795.49 Million
+6.57pp
2024-12-31 2.74% CN¥142.14 Million
≈ $20.80 Million
CN¥5.18 Billion
≈ $758.28 Million
+1.43pp
2023-12-31 1.31% CN¥63.29 Million
≈ $9.26 Million
CN¥4.83 Billion
≈ $706.71 Million
-12.02pp
2022-12-31 13.33% CN¥674.35 Million
≈ $98.68 Million
CN¥5.06 Billion
≈ $740.09 Million
+10.76pp
2021-12-31 2.57% CN¥106.02 Million
≈ $15.51 Million
CN¥4.13 Billion
≈ $603.90 Million
+1.63pp
2020-12-31 0.94% CN¥36.32 Million
≈ $5.31 Million
CN¥3.87 Billion
≈ $565.78 Million
-1.93pp
2019-12-31 2.87% CN¥94.32 Million
≈ $13.80 Million
CN¥3.29 Billion
≈ $480.76 Million
+0.11pp
2018-12-31 2.77% CN¥80.93 Million
≈ $11.84 Million
CN¥2.93 Billion
≈ $428.24 Million
-4.79pp
2017-12-31 7.55% CN¥208.00 Million
≈ $30.44 Million
CN¥2.75 Billion
≈ $402.99 Million
+6.71pp
2016-12-31 0.85% CN¥21.17 Million
≈ $3.10 Million
CN¥2.50 Billion
≈ $365.35 Million
-0.35pp
2015-12-31 1.20% CN¥28.81 Million
≈ $4.22 Million
CN¥2.41 Billion
≈ $352.64 Million
-1.19pp
2014-12-31 2.38% CN¥52.05 Million
≈ $7.62 Million
CN¥2.19 Billion
≈ $319.83 Million
+0.41pp
2013-12-31 1.97% CN¥39.98 Million
≈ $5.85 Million
CN¥2.03 Billion
≈ $296.68 Million
-0.06pp
2012-12-31 2.03% CN¥37.37 Million
≈ $5.47 Million
CN¥1.84 Billion
≈ $269.67 Million
-3.47pp
2011-12-31 5.49% CN¥91.07 Million
≈ $13.33 Million
CN¥1.66 Billion
≈ $242.56 Million
+1.34pp
2010-12-31 4.15% CN¥60.12 Million
≈ $8.80 Million
CN¥1.45 Billion
≈ $212.02 Million
+1.42pp
2009-12-31 2.73% CN¥39.15 Million
≈ $5.73 Million
CN¥1.44 Billion
≈ $210.11 Million
-10.32pp
2008-12-31 13.05% CN¥151.74 Million
≈ $22.20 Million
CN¥1.16 Billion
≈ $170.17 Million
+9.31pp
2007-12-31 3.74% CN¥40.84 Million
≈ $5.98 Million
CN¥1.09 Billion
≈ $159.74 Million
+3.61pp
2006-12-31 0.13% CN¥1.45 Million
≈ $211.62K
CN¥1.11 Billion
≈ $161.80 Million
+0.12pp
2003-12-31 0.01% CN¥50.59K
≈ $7.40K
CN¥367.95 Million
≈ $53.84 Million
-0.15pp
2002-12-31 0.16% CN¥580.07K
≈ $84.88K
CN¥363.13 Million
≈ $53.14 Million
+0.11pp
2001-12-31 0.05% CN¥151.42K
≈ $22.16K
CN¥320.89 Million
≈ $46.96 Million
--
pp = percentage points

About Mayinglong Pharmaceutical Group Co Ltd

SHG:600993 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.48 Billion
CN¥10.10 Billion CNY
Market Cap Rank
#7256 Global
#1562 in China
Share Price
CN¥23.42
Change (1 day)
-0.85%
52-Week Range
CN¥21.55 - CN¥30.12
All Time High
CN¥31.68
About

Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more